282 related articles for article (PubMed ID: 17896154)
1. Inhibition of proliferation by omega-3 fatty acids in chemoresistant pancreatic cancer cells.
Hering J; Garrean S; Dekoj TR; Razzak A; Saied A; Trevino J; Babcock TA; Espat NJ
Ann Surg Oncol; 2007 Dec; 14(12):3620-8. PubMed ID: 17896154
[TBL] [Abstract][Full Text] [Related]
2. G2/M cell-cycle arrest and apoptosis by n-3 fatty acids in a pancreatic cancer model.
Dekoj T; Lee S; Desai S; Trevino J; Babcock TA; Helton WS; Espat NJ
J Surg Res; 2007 May; 139(1):106-12. PubMed ID: 17291531
[TBL] [Abstract][Full Text] [Related]
3. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
4. Dimethylamino parthenolide enhances the inhibitory effects of gemcitabine in human pancreatic cancer cells.
Holcomb BK; Yip-Schneider MT; Waters JA; Beane JD; Crooks PA; Schmidt CM
J Gastrointest Surg; 2012 Jul; 16(7):1333-40. PubMed ID: 22618517
[TBL] [Abstract][Full Text] [Related]
5. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
6. PARP14 promotes the proliferation and gemcitabine chemoresistance of pancreatic cancer cells through activation of NF-κB pathway.
Yao N; Chen Q; Shi W; Tang L; Fu Y
Mol Carcinog; 2019 Jul; 58(7):1291-1302. PubMed ID: 30968979
[TBL] [Abstract][Full Text] [Related]
7. Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells.
Duong HQ; Hwang JS; Kim HJ; Kang HJ; Seong YS; Bae I
Int J Oncol; 2012 Sep; 41(3):855-61. PubMed ID: 22710732
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of proliferation to omega-3 fatty acids in chemoresistant pancreatic cancer cells: mechanism of action may be more complex.
Persaud R
Ann Surg Oncol; 2008 Jul; 15(7):2057. PubMed ID: 18351299
[No Abstract] [Full Text] [Related]
9. Alteration of the intrinsic apoptosis pathway is involved in Notch-induced chemoresistance to gemcitabine in pancreatic cancer.
Du X; Zhao YP; Zhang TP; Zhou L; Chen G; Wang TX; You L; Shu H
Arch Med Res; 2014 Jan; 45(1):15-20. PubMed ID: 24316112
[TBL] [Abstract][Full Text] [Related]
10. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM
Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists.
Morimoto M; Matsuo Y; Koide S; Tsuboi K; Shamoto T; Sato T; Saito K; Takahashi H; Takeyama H
BMC Cancer; 2016 May; 16():305. PubMed ID: 27175473
[TBL] [Abstract][Full Text] [Related]
12. [Mechanism of SPARC-enhanced chemosensitivity of pancreatic cancer cells to gemcitabine].
Zhang J; Jiang H; Mao Z; Wang X; Fan X; Liu Y; Wang Y
Zhonghua Zhong Liu Za Zhi; 2014 May; 36(5):335-40. PubMed ID: 25030587
[TBL] [Abstract][Full Text] [Related]
13. Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer.
Suzuki K; Aiura K; Matsuda S; Itano O; Takeuchi O; Umezawa K; Kitagawa Y
Clin Exp Metastasis; 2013 Apr; 30(4):381-92. PubMed ID: 23111540
[TBL] [Abstract][Full Text] [Related]
14. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
Horiuchi T; Uwagawa T; Shirai Y; Saito N; Iwase R; Haruki K; Shiba H; Ohashi T; Yanaga K
J Surg Res; 2016 Nov; 206(1):1-8. PubMed ID: 27916347
[TBL] [Abstract][Full Text] [Related]
15. Emodin sensitizes the gemcitabine-resistant cell line Bxpc-3/Gem to gemcitabine via downregulation of NF-κB and its regulated targets.
Zhang W; Chen H; Liu DL; Li H; Luo J; Zhang JH; Li Y; Chen KJ; Tong HF; Lin SZ
Int J Oncol; 2013 Apr; 42(4):1189-96. PubMed ID: 23440366
[TBL] [Abstract][Full Text] [Related]
16. (3E,5E)-3,5-Bis(pyridin-3-methylene)-tetrahydrothiopyran-4-one enhances the inhibitory effect of gemcitabine on pancreatic cancer cells.
Wu P; Wang X; Ma Y; Xu X; Liu W; Sheng Z; Chen M; Zhou R; Zhang K; Goodin S; Zheng X; Li D
Bioorg Chem; 2020 Aug; 101():104022. PubMed ID: 32599367
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine.
Duong HQ; Hong YB; Kim JS; Lee HS; Yi YW; Kim YJ; Wang A; Zhao W; Cho CH; Seong YS; Bae I
J Cell Mol Med; 2013 Oct; 17(10):1261-70. PubMed ID: 23855452
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies.
Holcomb B; Yip-Schneider MT; Matos JM; Dixon J; Kennard J; Mahomed J; Shanmugam R; Sebolt-Leopold J; Schmidt CM
J Gastrointest Surg; 2008 Feb; 12(2):288-96. PubMed ID: 18049840
[TBL] [Abstract][Full Text] [Related]
19. Irisin Enhances Doxorubicin-Induced Cell Apoptosis in Pancreatic Cancer by Inhibiting the PI3K/AKT/NF-κB Pathway.
Liu J; Huang Y; Liu Y; Chen Y
Med Sci Monit; 2019 Aug; 25():6085-6096. PubMed ID: 31412018
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine Resistance in Pancreatic Ductal Carcinoma Cell Lines Stems from Reprogramming of Energy Metabolism.
Fujiwara-Tani R; Sasaki T; Takagi T; Mori S; Kishi S; Nishiguchi Y; Ohmori H; Fujii K; Kuniyasu H
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
